A Phase 2 interventional study of ZED1227 and Placebo in NAFLD and Liver Fibrosis, sponsored by Dr. Falk Pharma GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Dr. Falk Pharma GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany — 14 open to participants now, 21 under way, 8 of them phase 3. Non-alcoholic Fatty Liver Disease · Germany.
Among the 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany, this one is the 38th largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2022, is one of 28 in phase 2, and was the 72nd registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →14 of the 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Germany, United States, Australia and 5 more countries
Ages 18–75
Eli Lilly and Company · Sites in Germany, United States, Argentina and 31 more countries
Ages 18+
Roche Diagnostics GmbH · Sites in Germany, Denmark
Ages 18–75
Akero Therapeutics, Inc · Sites in Germany, United States, Argentina and 20 more countries
Ages 18–80
Hoffmann-La Roche · Sites in Germany, United States, Argentina and 22 more countries
Ages 18–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 31 · Phase 3 18 · Phase 4 3
First in 2008; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 186 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 186 across the 75 interventional studies, 258 across the 14 observational. Of the 57 that completed or were terminated, 31 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 89 have an industry lead sponsor. The 10 most frequent:
Dr. Falk Pharma GmbH is the lead sponsor of 39 studies on the registry; 3 are open to participants now.
Dr. Falk Pharma GmbH has 2 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Non-alcoholic Fatty Liver Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06819917Roche Diagnostics GmbHIdentification of Liver Fibrosis Biomarkers | 2026-12 |
| NCT06396871Technische Universität DresdenDeep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases | 2026-12-31 |
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
Add all 3 to your calendar (.ics) → With an account.
Among the 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double-blind, randomized, multicenter, placebo-controlled, comparative, exploratory phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 20, 50, or 100 mg ZED1227 vs. placebo for the treatment of patients with NAFLD with fibrosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ZED1227
Drug: ZED1227
Drug: ZED1227
Drug: Placebo
ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
Placebo
Relative change of PRO-C3 levels
Relative change (%) of serum levels of PRO-C3 between baseline and the EOT.
Time frame: 12 weeks
Incidence of adverse events
Incidence of treatment-emergent adverse events.
Time frame: from baseline to 16 weeks
Ran from Apr 2022 to primary completion in Jun 2023, 13 months.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 13 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZED1227
Non-alcoholic Fatty Liver Disease →